Wockhardt Limited announced the release of an Investor Presentation scheduled for an Investor Meeting on June 4, 2026. This presentation, disclosed under Regulation 30 of SEBI (LODR) Regulations, 2015, provides an overview of the company's strategic direction, business performance, and growth drivers. The presentation highlights Wockhardt's global research-driven approach across Pharmaceuticals, Biotechnology, and Novel Antibiotics. Key financial metrics for FY26 include an income of ₹3,373 crore, EBITDA of ₹630 crore, and PBT of ₹238 crore, alongside a 51% year-over-year EBITDA growth. The company emphasizes its improved profitability through margin maximization and supply chain optimization, including the divestment of its US generic business. A significant focus is placed on the upcoming global launch of Zaynich, a novel antibiotic approved by the US FDA and CDSCO in India. The presentation details the significant market opportunity for Zaynich in addressing carbapenem-resistant infections in the US and emerging markets, including India. It outlines the clinical efficacy, safety profile, and the commercialization strategy, including the appointment of a new leadership team for Wockhardt USA. Future growth drivers include the expansion of the Novel Antibiotics business with Zaynich launches, enhancing the Biotech business for diabetes biosimilars, and accelerating growth in the Pharma business, particularly in India and the UK. The company aims for sustainable operational excellence driven by AI over the next two years.
